Found 52 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Requesting a reliance agreement with an external IRB. The purpose of this double-blind, placebo-controlled trial is to evaluate the safety and efficacy of treatment with plozasiran on the reduction of fasting serum TG from Baseline in subjects with Hypertriglyceridemia who have fasting TG levels between 150 mg/dL and 499 mg/dL.
This is a 12-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the safety and efficacy of daily subcutaneous metreleptin treatment in subjects with Familial Partial Lipodystrophy (FPLD). Subjects will be assigned to 1 of 3 groups depending on HbA1c and fasting TGs levels. Participants will complete 10 visits …
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of EFX in subjects with noninvasively diagnosed NASH/NAFLD. Subjects will be dosed QW with EFX 50 mg or placebo for up to 52 weeks. The safety and tolerability of EFX will be assessed during the study …
The goal of this is to evaluate the safety and effectiveness of the drug Ibudilast compared to placebo (an inactive pill) in reducing the number of drinking days and the amount of alcohol consumed by people who want to stop or reduce their drinking. Study duration 11 weeks and includes …
The main purpose of this study is to understand how patients with giant cell arteritis (GCA) respond to an investigational drug called abatacept (also called Orencia). Abatacept is being tested to determine if it is effective in treating GCA. An investigational drug is one that is not approved by the …
To demonstrate that the addition of ianalumab to standard first-line corticosteroids prolongs Time to Treatment Failure compared to Corticosteroids alone in participants with primary ITP. ITP means immune thrombocytopenia. Time from randomization to treatment failure which is defined as Platelet count below 30G/L after 8 weeks from randomization. Need for …
PURPOSE The overall objective is to demonstrate that the addition of ianalumab (either 3mg/kg or 9mg/kg dosage) to standard care (eltrombopag) is more effective and safer compared to the standard of care (eltrombopag) alone. Primary outcome variable is determined by the time to treatment failure which is in turn determined …
Penn Medicine patients already participating in protocol INS1007 301 will be invited to participate in this study. The Pharmacokinetic (PK) portion of this substudy is designed to evaluate the amount of brensocatib present in your blood at certain time periods before and after the study drug is administered, and the …
The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS. We would like to rely …
The purpose of this study is to find out if capivasertib given with paclitaxel is an effective treatment for triple negative breast cancer (TNBC). As part of this study subjects will receive paclitaxel in combination with either capivasertib or a placebo. Eligible subjects will be those diagnosed with metastatic (or …
